UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 13, 2024

BIOATLA, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation) 001-39787 (Commission File Number) 85-1922320 (IRS Employer Identification No.)

11085 Torreyana Road San Diego, California (Address of Principal Executive Offices)

92121 (Zip Code)

Registrant's Telephone Number, Including Area Code: 858 558-0708

| | (Former Nan | ne or Former Address, if Chang | ed Since Last Report) | |
|----|--|--------------------------------|--|--|
| | | | | |
| | ck the appropriate box below if the Form 8-K filing is interesting provisions: | ended to simultaneously sa | atisfy the filing obligation of the registrant under any of the | |
| | Written communications pursuant to Rule 425 under the | Securities Act (17 CFR 2 | 30.425) | |
| | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | | | |
| | Pre-commencement communications pursuant to Rule 14 | 4d-2(b) under the Exchang | ge Act (17 CFR 240.14d-2(b)) | |
| | Pre-commencement communications pursuant to Rule 13 | 3e-4(c) under the Exchang | ge Act (17 CFR 240.13e-4(c)) | |
| | Securities reg | istered pursuant to Sect | ion 12(b) of the Act: | |
| | | Trading | | |
| | Title of each class | Symbol(s) | Name of each exchange on which registered | |
| | Common Stock, \$0.0001 par value per share | BCAB | Nasdaq Global Market | |
| | cate by check mark whether the registrant is an emerging pter) or Rule 12b-2 of the Securities Exchange Act of 1934 | | ed in Rule 405 of the Securities Act of 1933 (§ 230.405 of this oter). | |
| Em | erging growth company | | | |
| | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | | | |

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Annual Meeting of Stockholders of BioAtla, Inc. (the "Company") was held online via live audio webcast on June 13, 2024 (the "Annual Meeting"). At the Annual Meeting, there were present, in person virtually or by proxy, holders of 34,513,932 shares of common stock, or approximately 71.75 % of the total outstanding shares eligible to be voted. The final voting results with respect to each proposal presented at the Annual Meeting is set forth below:

Proposal One - Election of Directors

The Company's stockholders approved the election of one Class I director to the Company's Board of Directors for a three-year term or until her successor is duly elected and qualified or until her earlier death, resignation, disqualification or removal, by the following votes:

| Nominee | Votes For | Votes Withheld | Broker Non-Votes |
|----------------|------------|-----------------------|-------------------------|
| Sylvia McBrinn | 15,280,856 | 7,634,075 | 11,599,001 |

Proposal Two - Ratification of Appointment of Independent Registered Public Accounting Firm

The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 by the following votes:

| Votes For | Votes Against | Abstentions |
|------------|---------------|-------------|
| 34,271,982 | 106,553 | 135,397 |

Proposal Three - Non-Binding Advisory Vote on the Executive Compensation of Our Named Executive Officers

The Company's stockholders approved, on a non-binding advisory basis, the executive compensation of our named executive officers by the following votes:

| Votes For | Votes Against | Abstentions | Broker Non-Votes |
|------------|---------------|-------------|-------------------------|
| 17.643.438 | 5.121.016 | 153.387 | 11.596.091 |

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned

| hereunto duly authorized. | | | |
|---------------------------|-----|-------------------------|--|
| | | BioAtla, Inc. | |
| Date: June 13, 2024 | Ву: | /s/ Richard A. Waldron | |
| | | Richard A. Waldron | |
| | | Chief Financial Officer | |
| | | | |
| | | | |
| | | | |
| | | | |